432 related articles for article (PubMed ID: 32504692)
21. A New Generation of Treatments for Itch.
Fowler E; Yosipovitch G
Acta Derm Venereol; 2020 Jan; 100(2):adv00027. PubMed ID: 31940047
[TBL] [Abstract][Full Text] [Related]
22. Effects of TS-022, a newly developed prostanoid DP1 receptor agonist, on experimental pruritus, cutaneous barrier disruptions and atopic dermatitis in mice.
Arai I; Takaoka A; Hashimoto Y; Honma Y; Koizumi C; Futaki N; Sugimoto M; Takahashi N; Inoue T; Nakanishi Y; Sakurai T; Tanami T; Yagi M; Ono N; Nakaike S
Eur J Pharmacol; 2007 Feb; 556(1-3):207-14. PubMed ID: 17141215
[TBL] [Abstract][Full Text] [Related]
23. Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.
Inan S; Torres-Huerta A; Jensen LE; Dun NJ; Cowan A
Eur J Pharmacol; 2019 Dec; 864():172702. PubMed ID: 31568781
[TBL] [Abstract][Full Text] [Related]
24. Itch in Atopic Dermatitis Management.
Kamata Y; Tominaga M; Takamori K
Curr Probl Dermatol; 2016; 50():86-93. PubMed ID: 27578076
[TBL] [Abstract][Full Text] [Related]
25. [Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis].
Nakao K; Ikeda K; Kurokawa T; Togashi Y; Umeuchi H; Honda T; Okano K; Mochizuki H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2008 Apr; 28(2):75-83. PubMed ID: 18516986
[TBL] [Abstract][Full Text] [Related]
26. Involvement of µ-opioid Receptors and κ-opioid Receptors in Itch-related Scratching Behaviour of Imiquimod-induced Psoriasis-like Dermatitis in Mice.
Takahashi N; Tominaga M; Kosaka R; Kamata Y; Umehara Y; Matsuda H; Sakaguchi A; Ogawa H; Takamori K
Acta Derm Venereol; 2017 Aug; 97(8):928-933. PubMed ID: 28512665
[TBL] [Abstract][Full Text] [Related]
27. Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out?
Mollanazar NK; Smith PK; Yosipovitch G
Clin Rev Allergy Immunol; 2016 Dec; 51(3):263-292. PubMed ID: 25931325
[TBL] [Abstract][Full Text] [Related]
28. Targeted treatment of pruritus: a look into the future.
Tey HL; Yosipovitch G
Br J Dermatol; 2011 Jul; 165(1):5-17. PubMed ID: 21219293
[TBL] [Abstract][Full Text] [Related]
29. An overview of drug discovery efforts for eczema: why is this itch so difficult to scratch?
Hon KL; Loo S; Leung AKC; Li JTS; Lee VWY
Expert Opin Drug Discov; 2020 Apr; 15(4):487-498. PubMed ID: 32050818
[No Abstract] [Full Text] [Related]
30. Itch Management: Systemic Agents.
Pongcharoen P; Fleischer AB
Curr Probl Dermatol; 2016; 50():46-53. PubMed ID: 27578071
[TBL] [Abstract][Full Text] [Related]
31. Opioid-induced pruritus: an update.
Reich A; Szepietowski JC
Clin Exp Dermatol; 2010 Jan; 35(1):2-6. PubMed ID: 19663845
[TBL] [Abstract][Full Text] [Related]
32. Addressing treatment challenges in atopic dermatitis with novel topical therapies.
Silverberg JI; Nelson DB; Yosipovitch G
J Dermatolog Treat; 2016 Nov; 27(6):568-576. PubMed ID: 27165566
[TBL] [Abstract][Full Text] [Related]
33. Nalfurafine prevents 5'-guanidinonaltrindole- and compound 48/80-induced spinal c-fos expression and attenuates 5'-guanidinonaltrindole-elicited scratching behavior in mice.
Inan S; Dun NJ; Cowan A
Neuroscience; 2009 Sep; 163(1):23-33. PubMed ID: 19524022
[TBL] [Abstract][Full Text] [Related]
34. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
[TBL] [Abstract][Full Text] [Related]
35. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.
Phan NQ; Bernhard JD; Luger TA; Ständer S
J Am Acad Dermatol; 2010 Oct; 63(4):680-8. PubMed ID: 20462660
[TBL] [Abstract][Full Text] [Related]
36. [Modern systemic therapy for pruritus].
Metz M; Pereira MP
Hautarzt; 2020 Jul; 71(7):518-524. PubMed ID: 32399670
[TBL] [Abstract][Full Text] [Related]
37. Immunomodulating Agents as Antipruritics.
Erickson S; Nahmias Z; Rosman IS; Kim BS
Dermatol Clin; 2018 Jul; 36(3):325-334. PubMed ID: 29929604
[TBL] [Abstract][Full Text] [Related]
38. An update on peripheral mechanisms and treatments of itch.
Tominaga M; Takamori K
Biol Pharm Bull; 2013; 36(8):1241-7. PubMed ID: 23902967
[TBL] [Abstract][Full Text] [Related]
39. Pilot evaluation of the antipruritic efficacy of a topical transient receptor potential melastatin subfamily 8 (TRPM8) agonist in dogs with atopic dermatitis and pedal pruritus.
Tamamoto-Mochizuki C; Murphy KM; Olivry T
Vet Dermatol; 2018 Feb; 29(1):29-e14. PubMed ID: 28952176
[TBL] [Abstract][Full Text] [Related]
40. Topical Application of ASN008, a Permanently Charged Sodium Channel Blocker, Shows Robust Efficacy, a Rapid Onset, and Long Duration of Action in a Mouse Model of Pruritus.
Ramachandran R; Thompson SK; Malkmus S; Mieda T; Lin JH; Gupta S; Yaksh TL
J Pharmacol Exp Ther; 2020 Sep; 374(3):521-528. PubMed ID: 32616515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
